Search results summary

From Health Canada

New search

Search criteria

  • Status: Select all
  • Company: CELLTRION INC.

Search results

List of returned drug products
Products returned by the search are listed, including their status, DIN number, name, class, total count of active ingredients and the name of one, etc. Clicking on the value in the DIN column returns more complete information about the related product.
Status DIN Company Product Class PM See footnote1 Schedule # See footnote2 A.I. name See footnote3 Strength
Approved 02562022 CELLTRION INC. AVTOZMA Human Yes Schedule D 1 TOCILIZUMAB 80 MG / 4 ML
Approved 02562022 CELLTRION INC. AVTOZMA Human Yes Prescription 1 TOCILIZUMAB 80 MG / 4 ML
Approved 02562030 CELLTRION INC. AVTOZMA Human Yes Prescription 1 TOCILIZUMAB 200 MG / 10 ML
Approved 02562030 CELLTRION INC. AVTOZMA Human Yes Schedule D 1 TOCILIZUMAB 200 MG / 10 ML
Approved 02562049 CELLTRION INC. AVTOZMA Human Yes Prescription 1 TOCILIZUMAB 400 MG / 20 ML
Approved 02562049 CELLTRION INC. AVTOZMA Human Yes Schedule D 1 TOCILIZUMAB 400 MG / 20 ML
Approved 02562057 CELLTRION INC. AVTOZMA Human Yes Schedule D 1 TOCILIZUMAB 162 MG / 0.9 ML
Approved 02562057 CELLTRION INC. AVTOZMA Human Yes Prescription 1 TOCILIZUMAB 162 MG / 0.9 ML
Approved 02562065 CELLTRION INC. AVTOZMA Human Yes Prescription 1 TOCILIZUMAB 162 MG / 0.9 ML
Approved 02562065 CELLTRION INC. AVTOZMA Human Yes Schedule D 1 TOCILIZUMAB 162 MG / 0.9 ML
Marketed 02480794 CELLTRION INC. HERZUMA Human Yes Prescription 1 TRASTUZUMAB 440 MG / VIAL
Marketed 02480794 CELLTRION INC. HERZUMA Human Yes Schedule D 1 TRASTUZUMAB 440 MG / VIAL
Marketed 02506211 CELLTRION INC. HERZUMA Human Yes Prescription 1 TRASTUZUMAB 150 MG / VIAL
Marketed 02506211 CELLTRION INC. HERZUMA Human Yes Schedule D 1 TRASTUZUMAB 150 MG / VIAL
Marketed 02553805 CELLTRION INC. OMLYCLO Human Yes Schedule D 1 OMALIZUMAB 75 MG / 0.5 ML
Marketed 02553805 CELLTRION INC. OMLYCLO Human Yes Prescription 1 OMALIZUMAB 75 MG / 0.5 ML
Marketed 02553813 CELLTRION INC. OMLYCLO Human Yes Schedule D 1 OMALIZUMAB 150 MG / 1 ML
Marketed 02553813 CELLTRION INC. OMLYCLO Human Yes Prescription 1 OMALIZUMAB 150 MG / 1 ML
Approved 02561018 CELLTRION INC. OMLYCLO Human Yes Schedule D 1 OMALIZUMAB 75 MG / 0.5 ML
Approved 02561018 CELLTRION INC. OMLYCLO Human Yes Prescription 1 OMALIZUMAB 75 MG / 0.5 ML
Approved 02561026 CELLTRION INC. OMLYCLO Human Yes Schedule D 1 OMALIZUMAB 150 MG / 1 ML
Approved 02561026 CELLTRION INC. OMLYCLO Human Yes Prescription 1 OMALIZUMAB 150 MG / 1 ML
Approved 02560895 CELLTRION INC. OSENVELT Human Yes Schedule D 1 DENOSUMAB 120 MG / 1.7 ML
Approved 02560895 CELLTRION INC. OSENVELT Human Yes Prescription 1 DENOSUMAB 120 MG / 1.7 ML
Marketed 02419475 CELLTRION INC. REMDANTRY Human Yes Prescription 1 INFLIXIMAB 100 MG / VIAL
Marketed 02419475 CELLTRION INC. REMDANTRY Human Yes Schedule D 1 INFLIXIMAB 100 MG / VIAL
Cancelled Post Market 02419483 CELLTRION INC. REMSIMA Human Yes Schedule D 1 INFLIXIMAB 100 MG / VIAL
Cancelled Post Market 02419483 CELLTRION INC. REMSIMA Human Yes Prescription 1 INFLIXIMAB 100 MG / VIAL
Approved 02511576 CELLTRION INC. REMSIMA SC Human Yes Prescription 1 INFLIXIMAB 120 MG / ML
Approved 02511576 CELLTRION INC. REMSIMA SC Human Yes Schedule D 1 INFLIXIMAB 120 MG / ML
Marketed 02511584 CELLTRION INC. REMSIMA SC Human Yes Schedule D 1 INFLIXIMAB 120 MG / ML
Marketed 02511584 CELLTRION INC. REMSIMA SC Human Yes Prescription 1 INFLIXIMAB 120 MG / ML
Marketed 02550245 CELLTRION INC. STEQEYMA Human Yes Prescription 1 USTEKINUMAB 45 MG / 0.5 ML
Marketed 02550245 CELLTRION INC. STEQEYMA Human Yes Schedule D 1 USTEKINUMAB 45 MG / 0.5 ML
Marketed 02550253 CELLTRION INC. STEQEYMA Human Yes Prescription 1 USTEKINUMAB 90 MG / 1 ML
Marketed 02550253 CELLTRION INC. STEQEYMA Human Yes Schedule D 1 USTEKINUMAB 90 MG / 1 ML
Approved 02558270 CELLTRION INC. STEQEYMA Human Yes Prescription 1 USTEKINUMAB 45 MG / 0.5 ML
Approved 02558270 CELLTRION INC. STEQEYMA Human Yes Schedule D 1 USTEKINUMAB 45 MG / 0.5 ML
Marketed 02550261 CELLTRION INC. STEQEYMA IV Human Yes Schedule D 1 USTEKINUMAB 5 MG / ML
Marketed 02550261 CELLTRION INC. STEQEYMA IV Human Yes Prescription 1 USTEKINUMAB 5 MG / ML
Approved 02560917 CELLTRION INC. STOBOCLO Human Yes Schedule D 1 DENOSUMAB 60 MG / ML
Approved 02560917 CELLTRION INC. STOBOCLO Human Yes Prescription 1 DENOSUMAB 60 MG / ML
Marketed 02478382 CELLTRION INC. TRUXIMA Human Yes Prescription 1 RITUXIMAB 100 MG / 10 ML
Marketed 02478382 CELLTRION INC. TRUXIMA Human Yes Schedule D 1 RITUXIMAB 100 MG / 10 ML
Marketed 02478390 CELLTRION INC. TRUXIMA Human Yes Schedule D 1 RITUXIMAB 500 MG / 50 ML
Marketed 02478390 CELLTRION INC. TRUXIMA Human Yes Prescription 1 RITUXIMAB 500 MG / 50 ML
Marketed 02534177 CELLTRION INC. VEGZELMA Human Yes Schedule D 1 BEVACIZUMAB 100 MG / 4 ML
Marketed 02534177 CELLTRION INC. VEGZELMA Human Yes Prescription 1 BEVACIZUMAB 100 MG / 4 ML
Marketed 02534185 CELLTRION INC. VEGZELMA Human Yes Schedule D 1 BEVACIZUMAB 400 MG / 16 ML
Marketed 02534185 CELLTRION INC. VEGZELMA Human Yes Prescription 1 BEVACIZUMAB 400 MG / 16 ML
Marketed 02523760 CELLTRION INC. YUFLYMA Human Yes Schedule D 1 ADALIMUMAB 40 MG / 0.4 ML
Marketed 02523760 CELLTRION INC. YUFLYMA Human Yes Prescription 1 ADALIMUMAB 40 MG / 0.4 ML
Marketed 02523779 CELLTRION INC. YUFLYMA Human Yes Schedule D 1 ADALIMUMAB 40 MG / 0.4 ML
Marketed 02523779 CELLTRION INC. YUFLYMA Human Yes Prescription 1 ADALIMUMAB 40 MG / 0.4 ML
Marketed 02535076 CELLTRION INC. YUFLYMA Human Yes Prescription 1 ADALIMUMAB 80 MG / 0.8 ML
Marketed 02535076 CELLTRION INC. YUFLYMA Human Yes Schedule D 1 ADALIMUMAB 80 MG / 0.8 ML
Marketed 02535084 CELLTRION INC. YUFLYMA Human Yes Prescription 1 ADALIMUMAB 80 MG / 0.8 ML
Marketed 02535084 CELLTRION INC. YUFLYMA Human Yes Schedule D 1 ADALIMUMAB 80 MG / 0.8 ML
Approved 02556596 CELLTRION INC. YUFLYMA Human Yes Prescription 1 ADALIMUMAB 20 MG / 0.2 ML
Approved 02556596 CELLTRION INC. YUFLYMA Human Yes Schedule D 1 ADALIMUMAB 20 MG / 0.2 ML
New search

Application information

Related information

Contact us

Version 4.0.3
Report a problem or mistake on this page

"Page details"

Date modified: